Trial Profile
A phase 2b study of IMR-687 for the treatment of sickle cell disease in pediatric patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs Tovinontrine (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- 23 Feb 2023 According to an Enliven Therapeutics media release, Imara Inc has merged with Enliven Therapeutics. The combined company will operate under the name, Enliven Therapeutics
- 05 Mar 2021 According to an Imara media release, it anticipates initiating a pediatric clinical program of IMR-687 in SCD in the first half of 2021
- 07 May 2020 According to an Imara media release, the company anticipates to begin screening in this study in the coming weeks with a continued goal of dosing the first patients by the end of the second quarter of 2020. While the ongoing COVID-19 pandemic may cause delays in initiation.